NCT04096638: Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors

NCT04096638
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Therapeutic Antibody, Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: TNBC patients are only eligible for the expansion phase
Exclusions: Patients with untreated unstable brain metastases- see trial for details
https://ClinicalTrials.gov/show/NCT04096638

Comments are closed.

Up ↑